查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1487527

糖尿病神经病变市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

Diabetic Neuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 251 Pages | 商品交期: 2-10个工作天内

价格

糖尿病神经病变市场 - 报告范围

TMR 关于全球糖尿病神经病变市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。年期间，考虑2024年为基准年，2034年为预测年。报告中也提供了2024年至2034年全球糖尿病神经病变市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解糖尿病神经病变市场。

市场概况
2023年市场价值 46 亿美元
2034 年市场价值 85 亿美元
复合年增长率 5.5%

该报告深入研究了全球糖尿病神经病变市场的竞争格局。全球糖尿病神经病变市场的主要参与者已被确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球糖尿病神经病变市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：主要见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依疾病类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依疾病类型，2020-2034
    • 週边神经病变
    • 自主神经病变
    • 近端神经病变
    • 局部神经病变
  • 市场吸引力分析：依无序类型

第 7 章：全球市场分析与预测：依治疗类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2020-2034
    • 药品
      • 止痛药
        • 专题
        • 阿片类药物
        • 非类固醇抗发炎药
      • 抗忧郁药
        • 三氯乙酸
        • SNRIs
        • SSRIs
      • 抗惊厥药
        • 加巴喷丁
        • 普瑞巴林
        • 托吡酯
        • 其他的
      • 其他药物
    • 放射治疗
      • 十
      • 其他的
    • 物理治疗
  • 市场吸引力分析：按治疗类型

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院
    • 诊所
    • 零售药局
    • 网路药局
  • 市场吸引力分析：按配销通路

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Johnson & Johnson (Janssen Global Services, LLC)
    • Boehringer Ingelheim GmbH
    • NeuroMetrix, Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Lupin Limited
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Arbor Pharmaceuticals, LLC
    • Depomed, Inc.
Product Code: TMRGL2199

Diabetic Neuropathy Market - Scope of Report

TMR's report on the global diabetic neuropathy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global diabetic neuropathy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global diabetic neuropathy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the diabetic neuropathy market.

Market Snapshot
Market Value in 2023US$ 4.6 Bn
Market Value in 2034US$ 8.5 Bn
CAGR5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global diabetic neuropathy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global diabetic neuropathy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global diabetic neuropathy market.

The report delves into the competitive landscape of the global diabetic neuropathy market. Key players operating in the global diabetic neuropathy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global diabetic neuropathy market profiled in this report.

Key Questions Answered in Global diabetic neuropathy Market Report:

  • What is the sales/revenue generated by diabetic neuropathy across all regions during the forecast period?
  • What are the opportunities in the global diabetic neuropathy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Diabetic Neuropathy Market - Research Objectives and Research Approach

The comprehensive report on the global diabetic neuropathy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global diabetic neuropathy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global diabetic neuropathy market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Diabetic Neuropathy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Diabetic Neuropathy Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Diabetic Neuropathy Market Analysis and Forecast, by Disorder Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 6.3.1. Peripheral Neuropathy
    • 6.3.2. Autonomic Neuropathy
    • 6.3.3. Proximal Neuropathy
    • 6.3.4. Focal Neuropathy
  • 6.4. Market Attractiveness Analysis, by Disorder Type

7. Global Diabetic Neuropathy Market Analysis and Forecast, by Treatment Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 7.3.1. Drugs
      • 7.3.1.1. Analgesics
        • 7.3.1.1.1. Topical
        • 7.3.1.1.1.1. Capsaicin
        • 7.3.1.1.1.2. Others
        • 7.3.1.1.2. Opioids
        • 7.3.1.1.2.1. Morphine
        • 7.3.1.1.2.2. Others
        • 7.3.1.1.3. NSAIDs
        • 7.3.1.1.3.1. Ibuprofen
        • 7.3.1.1.3.2. Naproxen
        • 7.3.1.1.3.3. Others
      • 7.3.1.2. Antidepressants
        • 7.3.1.2.1. TCAs
        • 7.3.1.2.1.1. Amitriptyline
        • 7.3.1.2.1.2. Imipramine
        • 7.3.1.2.1.3. Others
        • 7.3.1.2.2. SNRIs
        • 7.3.1.2.2.1. Duloxetine
        • 7.3.1.2.2.2. Others
        • 7.3.1.2.3. SSRIs
        • 7.3.1.2.3.1. Citalopram
        • 7.3.1.2.3.2. Paroxetin
        • 7.3.1.2.3.3. Others
      • 7.3.1.3. Anticonvulsants
        • 7.3.1.3.1. Gabapentin
        • 7.3.1.3.2. Pregabalin
        • 7.3.1.3.3. Topimarate
        • 7.3.1.3.4. Others
      • 7.3.1.4. Other Drugs
    • 7.3.2. Radiotherapy
      • 7.3.2.1. TENS
      • 7.3.2.2. Others
    • 7.3.3. Physiotherapy
  • 7.4. Market Attractiveness Analysis, by Treatment Type

8. Global Diabetic Neuropathy Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Retail Pharmacies
    • 8.3.4. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Diabetic Neuropathy Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Diabetic Neuropathy Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 10.3.1. Peripheral Neuropathy
    • 10.3.2. Autonomic Neuropathy
    • 10.3.3. Proximal Neuropathy
    • 10.3.4. Focal Neuropathy
  • 10.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 10.4.1. Drugs
      • 10.4.1.1. Analgesics
        • 10.4.1.1.1. Topical
        • 10.4.1.1.1.1. Capsaicin
        • 10.4.1.1.1.2. Others
        • 10.4.1.1.2. Opioids
        • 10.4.1.1.2.1. Morphine
        • 10.4.1.1.2.2. Others
        • 10.4.1.1.3. NSAIDs
        • 10.4.1.1.3.1. Ibuprofen
        • 10.4.1.1.3.2. Naproxen
        • 10.4.1.1.3.3. Others
      • 10.4.1.2. Antidepressants
        • 10.4.1.2.1. TCAs
        • 10.4.1.2.1.1. Amitriptyline
        • 10.4.1.2.1.2. Imipramine
        • 10.4.1.2.1.3. Others
        • 10.4.1.2.2. SNRIs
        • 10.4.1.2.2.1. Duloxetine
        • 10.4.1.2.2.2. Others
        • 10.4.1.2.3. SSRIs
        • 10.4.1.2.3.1. Citalopram
        • 10.4.1.2.3.2. Paroxetin
        • 10.4.1.2.3.3. Others
      • 10.4.1.3. Anticonvulsants
        • 10.4.1.3.1. Gabapentin
        • 10.4.1.3.2. Pregabalin
        • 10.4.1.3.3. Topimarate
        • 10.4.1.3.4. Others
      • 10.4.1.4. Other Drugs
    • 10.4.2. Radiotherapy
      • 10.4.2.1. TENS
      • 10.4.2.2. Others
    • 10.4.3. Physiotherapy
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospitals
    • 10.5.2. Clinics
    • 10.5.3. Retail Pharmacies
    • 10.5.4. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Disorder Type
    • 10.7.2. By Treatment Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Diabetic Neuropathy Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 11.3.1. Peripheral Neuropathy
    • 11.3.2. Autonomic Neuropathy
    • 11.3.3. Proximal Neuropathy
    • 11.3.4. Focal Neuropathy
  • 11.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.4.1. Drugs
      • 11.4.1.1. Analgesics
        • 11.4.1.1.1. Topical
        • 11.4.1.1.1.1. Capsaicin
        • 11.4.1.1.1.2. Others
        • 11.4.1.1.2. Opioids
        • 11.4.1.1.2.1. Morphine
        • 11.4.1.1.2.2. Others
        • 11.4.1.1.3. NSAIDs
        • 11.4.1.1.3.1. Ibuprofen
        • 11.4.1.1.3.2. Naproxen
        • 11.4.1.1.3.3. Others
      • 11.4.1.2. Antidepressants
        • 11.4.1.2.1. TCAs
        • 11.4.1.2.1.1. Amitriptyline
        • 11.4.1.2.1.2. Imipramine
        • 11.4.1.2.1.3. Others
        • 11.4.1.2.2. SNRIs
        • 11.4.1.2.2.1. Duloxetine
        • 11.4.1.2.2.2. Others
        • 11.4.1.2.3. SSRIs
        • 11.4.1.2.3.1. Citalopram
        • 11.4.1.2.3.2. Paroxetin
        • 11.4.1.2.3.3. Others
      • 11.4.1.3. Anticonvulsants
        • 11.4.1.3.1. Gabapentin
        • 11.4.1.3.2. Pregabalin
        • 11.4.1.3.3. Topimarate
        • 11.4.1.3.4. Others
      • 11.4.1.4. Other Drugs
    • 11.4.2. Radiotherapy
      • 11.4.2.1. TENS
      • 11.4.2.2. Others
    • 11.4.3. Physiotherapy
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Retail Pharmacies
    • 11.5.4. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Disorder Type
    • 11.7.2. By Treatment Type
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Diabetic Neuropathy Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 12.3.1. Peripheral Neuropathy
    • 12.3.2. Autonomic Neuropathy
    • 12.3.3. Proximal Neuropathy
    • 12.3.4. Focal Neuropathy
  • 12.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.4.1. Drugs
      • 12.4.1.1. Analgesics
        • 12.4.1.1.1. Topical
        • 12.4.1.1.1.1. Capsaicin
        • 12.4.1.1.1.2. Others
        • 12.4.1.1.2. Opioids
        • 12.4.1.1.2.1. Morphine
        • 12.4.1.1.2.2. Others
        • 12.4.1.1.3. NSAIDs
        • 12.4.1.1.3.1. Ibuprofen
        • 12.4.1.1.3.2. Naproxen
        • 12.4.1.1.3.3. Others
      • 12.4.1.2. Antidepressants
        • 12.4.1.2.1. TCAs
        • 12.4.1.2.1.1. Amitriptyline
        • 12.4.1.2.1.2. Imipramine
        • 12.4.1.2.1.3. Others
        • 12.4.1.2.2. SNRIs
        • 12.4.1.2.2.1. Duloxetine
        • 12.4.1.2.2.2. Others
        • 12.4.1.2.3. SSRIs
        • 12.4.1.2.3.1. Citalopram
        • 12.4.1.2.3.2. Paroxetin
        • 12.4.1.2.3.3. Others
      • 12.4.1.3. Anticonvulsants
        • 12.4.1.3.1. Gabapentin
        • 12.4.1.3.2. Pregabalin
        • 12.4.1.3.3. Topimarate
        • 12.4.1.3.4. Others
      • 12.4.1.4. Other Drugs
    • 12.4.2. Radiotherapy
      • 12.4.2.1. TENS
      • 12.4.2.2. Others
    • 12.4.3. Physiotherapy
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Retail Pharmacies
    • 12.5.4. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Disorder Type
    • 12.7.2. By Treatment Type
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Diabetic Neuropathy Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 13.3.1. Peripheral Neuropathy
    • 13.3.2. Autonomic Neuropathy
    • 13.3.3. Proximal Neuropathy
    • 13.3.4. Focal Neuropathy
  • 13.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.4.1. Drugs
      • 13.4.1.1. Analgesics
        • 13.4.1.1.1. Topical
        • 13.4.1.1.1.1. Capsaicin
        • 13.4.1.1.1.2. Others
        • 13.4.1.1.2. Opioids
        • 13.4.1.1.2.1. Morphine
        • 13.4.1.1.2.2. Others
        • 13.4.1.1.3. NSAIDs
        • 13.4.1.1.3.1. Ibuprofen
        • 13.4.1.1.3.2. Naproxen
        • 13.4.1.1.3.3. Others
      • 13.4.1.2. Antidepressants
        • 13.4.1.2.1. TCAs
        • 13.4.1.2.1.1. Amitriptyline
        • 13.4.1.2.1.2. Imipramine
        • 13.4.1.2.1.3. Others
        • 13.4.1.2.2. SNRIs
        • 13.4.1.2.2.1. Duloxetine
        • 13.4.1.2.2.2. Others
        • 13.4.1.2.3. SSRIs
        • 13.4.1.2.3.1. Citalopram
        • 13.4.1.2.3.2. Paroxetin
        • 13.4.1.2.3.3. Others
      • 13.4.1.3. Anticonvulsants
        • 13.4.1.3.1. Gabapentin
        • 13.4.1.3.2. Pregabalin
        • 13.4.1.3.3. Topimarate
        • 13.4.1.3.4. Others
      • 13.4.1.4. Other Drugs
    • 13.4.2. Radiotherapy
      • 13.4.2.1. TENS
      • 13.4.2.2. Others
    • 13.4.3. Physiotherapy
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Retail Pharmacies
    • 13.5.4. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Disorder Type
    • 13.7.2. By Treatment Type
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Diabetic Neuropathy Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 14.3.1. Peripheral Neuropathy
    • 14.3.2. Autonomic Neuropathy
    • 14.3.3. Proximal Neuropathy
    • 14.3.4. Focal Neuropathy
  • 14.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.4.1. Drugs
      • 14.4.1.1. Analgesics
        • 14.4.1.1.1. Topical
        • 14.4.1.1.1.1. Capsaicin
        • 14.4.1.1.1.2. Others
        • 14.4.1.1.2. Opioids
        • 14.4.1.1.2.1. Morphine
        • 14.4.1.1.2.2. Others
        • 14.4.1.1.3. NSAIDs
        • 14.4.1.1.3.1. Ibuprofen
        • 14.4.1.1.3.2. Naproxen
        • 14.4.1.1.3.3. Others
      • 14.4.1.2. Antidepressants
        • 14.4.1.2.1. TCAs
        • 14.4.1.2.1.1. Amitriptyline
        • 14.4.1.2.1.2. Imipramine
        • 14.4.1.2.1.3. Others
        • 14.4.1.2.2. SNRIs
        • 14.4.1.2.2.1. Duloxetine
        • 14.4.1.2.2.2. Others
        • 14.4.1.2.3. SSRIs
        • 14.4.1.2.3.1. Citalopram
        • 14.4.1.2.3.2. Paroxetin
        • 14.4.1.2.3.3. Others
      • 14.4.1.3. Anticonvulsants
        • 14.4.1.3.1. Gabapentin
        • 14.4.1.3.2. Pregabalin
        • 14.4.1.3.3. Topimarate
        • 14.4.1.3.4. Others
      • 14.4.1.4. Other Drugs
    • 14.4.2. Radiotherapy
      • 14.4.2.1. TENS
      • 14.4.2.2. Others
    • 14.4.3. Physiotherapy
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospitals
    • 14.5.2. Clinics
    • 14.5.3. Retail Pharmacies
    • 14.5.4. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Disorder Type
    • 14.7.2. By Treatment Type
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Johnson & Johnson (Janssen Global Services, LLC)
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Boehringer Ingelheim GmbH
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. NeuroMetrix, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Eli Lilly and Company
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. GlaxoSmithKline plc
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Lupin Limited
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Astellas Pharma Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Glenmark Pharmaceuticals Ltd.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Arbor Pharmaceuticals, LLC
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Depomed, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview

List of Tables

  • Table 01: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 02: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 03: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 07: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 08: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 11: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 12: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 15: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 16: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 19: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 20: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 23: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 24: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Diabetic Neuropathy Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Diabetic Neuropathy Market Revenue (US$ Mn), by Disorder Type, 2023
  • Figure 03: Global Diabetic Neuropathy Market Value Share, by Disorder Type, 2023
  • Figure 04: Global Diabetic Neuropathy Market Revenue (US$ Mn), by Treatment Type, 2023
  • Figure 05: Global Diabetic Neuropathy Market Value Share, by Treatment Type, 2023
  • Figure 06: Global Diabetic Neuropathy Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 07: Global Diabetic Neuropathy Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Diabetic Neuropathy Market Value Share, by Region, 2023
  • Figure 09: Global Diabetic Neuropathy Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 11: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 13: Global Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 14: Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Diabetic Neuropathy Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Diabetic Neuropathy Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Diabetic Neuropathy Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 22: North America Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 23: North America Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 26: North America Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 31: Europe Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 32: Europe Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 35: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 40: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 41: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 44: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 49: Latin America Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 50: Latin America Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 53: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 58: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 59: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 62: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034